Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

NCT02912364 ·Status: COMPLETED ·Phase: PHASE4

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247 ·Status: COMPLETED ·Phase: PHASE3

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

NCT02777671 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

NCT00957372 ·Status: COMPLETED ·Phase: PHASE3

Anti-epileptogenic Effects of Eslicarbazepine Acetate

NCT06597084 ·Status: COMPLETED ·Phase: PHASE2

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

NCT03082222 ·Status: COMPLETED

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

NCT02283788 ·Status: COMPLETED ·Phase: PHASE1

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

NCT01532726 ·Status: COMPLETED

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

NCT01162460 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

NCT00866775 ·Status: COMPLETED ·Phase: PHASE3

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

NCT02283814 ·Status: COMPLETED ·Phase: PHASE1

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

NCT03108729 ·Status: WITHDRAWN ·Phase: PHASE3

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

NCT02484001 ·Status: COMPLETED ·Phase: PHASE3

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

NCT00898560 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

NCT00900237 ·Status: COMPLETED ·Phase: PHASE1

Cardiovascular Risk Reduction in Epilepsy

NCT05704439 ·Status: WITHDRAWN ·Phase: NA

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

NCT02281591 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

NCT00957047 ·Status: COMPLETED ·Phase: PHASE3

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

NCT01879332 ·Status: COMPLETED ·Phase: PHASE1

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

NCT00988429 ·Status: COMPLETED ·Phase: PHASE3

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

NCT01527513 ·Status: COMPLETED ·Phase: PHASE2

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

NCT01332513 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

NCT00957684 ·Status: COMPLETED ·Phase: PHASE3

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

NCT02283827 ·Status: COMPLETED ·Phase: PHASE1